Theresa Werner, MD
Theresa L. Werner, M.D., is a Professor in the Division of Oncology, Department of Medicine, at the University of Utah School of Medicine, an Investigator at the Huntsman Cancer Institute, and a member of the Experimental Therapeutics Program. Dr. Werner is a specialist in adult medical oncology, and her main areas of interest include gynecologic malignancies (cancers of the ovary, uterus, cervix, and vagina). Dr. Werner earned her bachelor’s degree from Indiana University in Bloomington, Indiana, and her medical degree from Indiana University School of Medicine, in Indianapolis, Indiana. She then completed a residency in internal medicine and a chief medical residency at the University of Utah School of Medicine, where she received awards for excellence in teaching and the clinical care of patients. Dr. Werner then completed a fellowship in hematology and medical oncology at the University of Utah and the Huntsman Cancer Institute. She is board certified in medical oncology. Dr. Werner is a member of several professional societies including the American Society of Clinical Oncology and NRG Oncology including the Gynecology Oncology Group. She also serves on the National Cancer Institute’s Gynecologic Cancer Steering Committee and the National Cancer Comprehensive Network (NCCN) Panel for Ovarian Cancer, which defines national standards for the oncologic care of ovarian cancer, as well as NCCN Patient Guidelines and NCCN Chemotherapy Templates groups. Dr. Werner is heavily involved in clinical and translational research and is active in the experimental therapeutics and phase one clinical trial program. She was the Medical Director of the Clinical Trials Office at HCI until 2022. She is the 2016 recipient of the NCI Cancer Clinical Investigator Team Leadership Award. Dr. Werner serves as the principal investigator for numerous clinical trials in gynecologic cancers. Dr. Werner recently completed her three-year tenure as the Chair of the Association of American Cancer Institutes (AACI) Clinical Research Innovation (CRI) Steering Committee.
Financial relationships
-
Attribution:SelfType of financial relationship:OtherIneligible company:Mersana TherapeuticsTopic:Advisor for clincial trialDate added:09/29/2022Date updated:09/29/2022Relationship end date:05/01/2022